Brief: Vectivbio Reports Positive Interim Clinical Data From Stars Nutrition, A Phase 2 Study Investigating Apraglutide In Short Bowel Syndrome With Intestinal Failure Patients

VectivBio Holding AG

13/10/2022 12:05

Oct 13 (Reuters) - VectivBio Holding AG  VECT.O :
    * VECTIVBIO REPORTS POSITIVE INTERIM CLINICAL DATA
FROM STARS
NUTRITION, A PHASE 2 STUDY INVESTIGATING APRAGLUTIDE IN SHORT
BOWEL SYNDROME WITH INTESTINAL FAILURE PATIENTS (SBS-IF) WITH
COLON-IN-CONTINUITY (CIC)
    * TREATMENT WITH APRAGLUTIDE RESULTED IN AN AVERAGE 50%
REDUCTION
IN PARENTERAL SUPPORT (PS) VOLUME AT SIX MONTHS
    * 80% OF PATIENTS WERE CLINICAL RESPONDERS AND ACHIEVED AT
LEAST
ONE DAY OFF PS AT SIX MONTHS
    * IN NINE PATIENTS WHO REACHED AT LEAST THREE MONTHS OF
TREATMENT,
AVERAGE PS REDUCTION WAS 31% AFTER THREE MONTHS OF TREATMENT

Source text for Eikon:  ID:nGNX7jDqyF 
Further company coverage:  VECT.O